Wednesday, July 8, 2026

Patent intelligence · US

US 11479576

Nucleic acid prodrugs

granted A61PA61P1/00A61P1/16A61P21/00
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 16
Applicant portfolio 10
Patent details — US 11479576
Jurisdiction
US
Status
granted
Grant date
Oct 25, 2022
Expiration
Oct 20, 2042
Claims
3
CPC classes
A61P, A61P1/00, A61P1/16, A61P21/00
View on Google Patents ↗

Quick answer

US 11479576 (Nucleic acid prodrugs) is held by AVALO THERAPEUTICS, INC.. Status: granted. Granted Oct 25, 2022. Expires Oct 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
3
CPC classes
A61P, A61P1/00, A61P1/16, A61P21/00, A61P25/00, A61P43/00

More from AVALO THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12410153

    Compounds, compositions and methods

    AVALO THERAPEUTICS, INC. · Expires Sep 4, 2045

    granted
  2. US 12331107

    Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody

    AVALO THERAPEUTICS, INC. · Expires Jun 12, 2045

    granted
  3. US 11939368

    QTY Fc fusion receptor proteins

    Avalon GloboCare Corp. · Expires Mar 21, 2044

    granted
  4. US 11898180

    Compositions and methods for amino acid depletion therapy

    Avalon Polytom (HK) Limited · Expires Feb 8, 2044

    granted
  5. US 11850243

    Dihydropyridine compositions and methods for treating neurological disorders

    Cavalon Therapeutics, Inc. · Expires Dec 21, 2043

    granted
  6. US 11708406

    Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody

    AVALO THERAPEUTICS, INC. · Expires Jul 20, 2043

    granted
  7. US 11555060

    QTY FC fusion water soluble receptor proteins

    Avalon GloboCare Corp. · Expires Jan 12, 2043

    granted

Frequently asked questions

What is US patent 11479576?

US 11479576 (Nucleic acid prodrugs) is held by AVALO THERAPEUTICS, INC.. Status: granted. Granted Oct 25, 2022. Expires Oct 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11479576?

AVALO THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.

When does US 11479576 expire?

Our index shows an expiration date of Oct 20, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.